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ABSTRACT 
Contagious bovine pleuropneumonia (CBPP), caused by Mycoplasma mycoides subsp. 
mycoides biotype Small Colony (MmmSC), is one of the most serious cattle diseases in 
Africa. Its eradication still requires the development of efficient long tenn protective 
vaccines. To this aim, current researches are dedicated to: 1) the characterization of the 
protective immune parameters and the understanding of the immunopatbological 
mechanisms and 2) the development of improved vaccine strategies either relying on 
the identification of potential MmmSC vaccine antigens and relevant delivery systems 
for the development of sub unit vaccines or based on recombinant MmmSC vaccines by 
inactivation of selected virulent factors . A review of the scientific results and vaccinal 
strategies will be presented. 
INTRODUCTION AND RATIONALE 
Contagious bovine pleuropneumonia (CBPP), caused by Mycoplasma 
mycoides subsp. mycoides SC (MmmSC), remains one of the major cattle 
diseases in Africa. It is responsible for heavy economic losses and is 
included in the OIE list of pathologies requiring official declaration. 
lnfected countries are thus excluded from international trade. Improved 
vaccines are the only realistic prophylaxis to eradicate it from Africa, 
since 1) live attenuated Tl vaccines currently in use are of low efficacy 
requiring annual, costly, vaccination campaigns and 2) the combination 
of stamping-out, cattle movement control and quarantine used in other 
continents to eradicate CBPP is impracticable in Africa where cattle 
raising relies on nomadism and transhumance. Development of optimised 
long-term protective vaccines against CBPP is thus a necessity. 
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VACCINE STRA TEGY A GAIN ST CBPP 
The vaccinal strategy is determined by 1) the protective immune 
parameters to trigger, 2) the MmmSC components to include and 3) the 
immunopathological mechanisms to control. 
Protective immune parameters 
The feasibility of triggering a protective immune response by vaccination 
is sustained by the fact that cattle recovering from an MmmSC infection 
are then protected against any new MmmSC contact. Recovered cattle, 
therefore, not only succeed in controlling the infection by mounting a 
relevant immune response, but also retained in their lymph nodes, an 
MmmSC-specific memory immune response. The characterisation of the 
underlying immune parameters can thus allow defining the main actors in 
protection against MmmSC. To this aim, several studies were 
implemented in CIRAD in collaboration with African partners 
(LANA VET in Cameroon, CYL in Mali, OVI in South Africa). 
Experimental MmmSC infections were done locally, as described by 
Niang et al. (2004) and comparative analysis were performed between 
animais recovering or dying from the infection. The MmmSC-specific 
humoral and cellular response was evaluated. The results revealed that 
recovered animais were characterised by 1) a stronger and persisting 
local IgA response (Niang et al, 2006) and 2) a higher MmmSC-specific 
CD4 T-cell-mediated response with IFNy production (Dedieu et al, 2005, 
2006). Therefore, both arms of the immune system play a role in 
protection against CBPP, the local humoral response relying on IgAs and 
the cellular response based on Thl-like CD4 T-cells. Both represent thus 
the main targets of an optimised vaccine against CBPP. 
Immunopathological aspect of CBPP 
Understanding the immunopathological aspects of CBPP is also an 
important step for a rational design of the vaccine. Indeed, stimulating a 
vaccine-induced immune response against MmmSC implies that the host 
still maintains its ability to mount an efficient response when in contact 
with MmmSC. However, MmmSC possess immunosuppressive properties 
(ability to survive in lung lesions and lymph nodes of infected cattle 
(Bashiruddin et al. , 2005 ; Scanziani et al., 1997). To characterise this 
effect, the interaction between MmmSC and bovine immune cells was 
analysed. The results demonstrated that 1) viable MmmSC can trigger 
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apoptosis of the bovine leukocytes, 2) MmmSC-secreted components 
appears to be responsible (Dedieu et al. , 2005b) and 3) viable MmmSC 
depress the ConA T-cell mitogenic activity (Dedieu et al., 2006b). These 
data confirm that MmmSC had evolved an efficient way to escape the 
bovine immune response which might hamper vaccine efficacy. Blocking 
the MmmSC component(s) involved can thus also represent an important 
vaccinal target. 
Potential MmmSC vaccine candidates 
Considering the need to elicit an antibody as well as a cellular immune 
response, MmmSC vaccine candidates have to be selected on these two 
criteria. Selection th us relies on 1) screening MmmSC libraries with 
relevant sera to detect proteins with B-cell epitopes (IgA, IgG2) and 2) 
screening of MmmSC components by in vitro T-cell assays. Using 
antibody screening, a panel of MmmSC components has already been 
selected for which T-cell screening is underway. Indeed, several proteins 
did contain B- and T-cell epitopes. This approach is the most rationale 
for sub-unit or recombinant CBPP vaccines. Other approaches such as 
attenuated CBPP vaccines relying on inactivation of selected virulent 
factors also exist. 
Identification of a relevant vaccinal delivery system 
and route of delivery 
The trend in vaccine development now focuses on sub-unit vaccines. 
However, purified proteins are often of low irnmunogenicity. Vaccine 
efficacy thus requires the addition of relevant immunostimulating 
molecule and delivery system to enhance the immune response. Their 
choice depends mainly on the type of immune response to be triggered, 
which, for CBPP, relies on CD4 IFNy-secreting T-cells and local IgAs. 
This determines that, for the development of an efficient CBPP vaccine, 
1) Thl-inducing adjuvant and delivery system should be used and 2) the 
most efficient route of delivery is mucosal (oral or intra-nasal). 
CONCLUSION 
The scientific results obtained allow defining the best immune strategy 
for the development of a CBPP vaccine with optimal efficacy. Indeed, 
they determine i) the type of MmmSC vaccinal antigens to be selected, ii) 
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the immune mechanisms to be stimulated by the vaccine and iii) the most 
appropriate route and delivery system for optimal efficacy. 
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